HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

TRLV

Trulieve Cannabis Corp. (NYSE)

Healthcare — Drug Manufacturers - Specialty & Generic

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.

Strong Buy 1.1 / 5 1 analysts
$9.60
+$0.06 (+0.58%)
Target: $21.00 (118.9%)
Sign in to add TRLV to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.85B
P/E Ratio (TTM)-
Forward P/E39.98
EPS (TTM)$-0.40
Dividend Yield-
Profit Margin-6.93%
Revenue Growth-3.70%
ROE-6.85%
Debt/Equity54.80
Recommendation Strong Buy 1.1
Analyst Target$21.00
Analysts1
Indexes NYSE

Technical Indicators

RSI (14)34.0
Beta1.86
SMA 20-
SMA 40-
52-Week High$13.28
52-Week Low$3.80
50-Day Avg$9.20
200-Day Avg$7.61
Avg Volume977.5K
Volume37.3K

Performance Analysis

NEUTRAL

TRLV presents a mixed picture with both positive and negative indicators.

~ Trading at 61% of its 52-week range.
~ RSI at 34.0 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- Revenue declined 3.7% year-over-year.
- Operating at a loss with -6.9% margin.
+ Wall Street consensus is "Strong Buy" from 1 analysts.
+ Average analyst target of $21.00 implies 118.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:34 UTC

Back to Screener Export Report